China, Nov. 10 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Research on Immune-related Adverse Reactions Treated with adalimumab'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600136201
Registration Time: 2026/11/06
Type: Interventional study
Primary Sponsor: Fujian Cancer Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=332446
Published by HT Digital Content Services with permission from Health Daily Digest....